R3CE (Rapid, Reproducible, Rare Cell 3D Expansion) is a clinically validated platform capable of generating single cell-derived organoids within one to four weeks. It outperforms currently 3D culture technologies in terms of yields, time to form organoids,easiness of operation. It also demonstrates similar yieldscost structure to 2D culture protocols. R3CE is ready for drug testing for all clinical samplesprovides sufficient quantity of genomic samples derived from cancer patients. It would help conduct clinical cancer treatment in the translational study.

The invention integrates a variety of technologies including stem cell proliferation, directed inductioncryopreservation in vitro. This integrated system was developed under chemical defined condition,can expand various type of stem cells over one hundred foldcan furtherly induce to specific mature cells up to ten millions. In addition, the amount of cryoprotectant can be significantly reduced to 2 in the cryopreservation system with excellent cell survival rate. This integrated system can provide a promisingvarious stem cell sources for cell therapyimmunotherapy.

A microfluidic diffraction device is developed for determination of CTC/bacteria from human whole blood with a home-constructed laser beam system. We design the optical structuretransfer the structure to transparent plastic substrate. The plastic diffraction die is modified with antibodies of the target to combine a fluidic system as a microfluidic diffraction chip. When human whole blood with CTCs/bacteria flows through the chip, the number of cells/bacteria can be obtained directly with label-free. The devices has been applied in clinical diagnosis of oesophagealendometrial cancer.

Lung-on-minilab is designed as a tool for personalized healthcarewill contribute in precision medicine. Here, the tumor microenvironment was reconstituted using liquid dielectrophoresisarranged as lung tissue. The size of pattern can be customized as stages of cancer. Additionally, this chip was equipped a gradient microfluidic channel which enabled testing combination of medications. This is the first device where chemotherapyimmunotherapy medications can be tested together. This will improve the screening timeserve as an alternative for patients in therapeutic try.

A stem cell continuous harvest method was proposed. In this method, stem cells are partially detached. The remaining cells are continuously cultured by expansion in fresh culture medium.